

The quest for **long-acting** technologies resources



“

I need support to develop my LA candidate further, so making it visible helps.

I want to make sure the target populations have access to the final product.

I want to build on previous work and engage in enriching collaborations.”



“

A portfolio with baseline information on LA technologies would be very helpful to preliminarily assess potential matches between LA platforms and active pharmaceutical ingredients.”



“

A readily available and updated source of information in this emerging field is helpful for decision making and funding prioritisation.”



“

We welcome insights into upcoming products, tech and manufacturing aspects. The patents & licences summary is very helpful.”



“

A resource with reliable and updated information on the diversity of products and their related IP, that is user-friendly, can be used as support for advocacy, engage end-users and inform choices.”

LAPaL

THE LONG-ACTING TECHNOLOGIES
PATENTS AND LICENCES DATABASE

A new collaborative
tool supporting
access to innovation
in the long-acting
space

What is LAPaL ?

LAPaL is a compilation of **technical** and **intellectual property** information on long-acting technologies and their potential applications.

It aims to facilitate collaborations and advocate for **access**, in particular for for users in **low- and middle-income countries**.



USER-FRIENDLY



COLLABORATIVE



FREE & PUBLIC



SEARCHABLE




EXPORTABLE
RESULTS



REGULARLY
UPDATED

What are LAPaL's main components?

LONG-ACTING TECHNOLOGIES
features, applications, development
& manufacturing information



IP LANDSCAPE
with focus on low-
and middle-income
countries

ACCESS
COMMITMENTS
from innovators to foster
pipeline acceleration



[All technologies](#)

[Submit a technology](#)

[Access principles](#)

[News](#)

[Information](#)

[Contact](#)

[Login](#)

Technology name, API or developer

Clear

Route(s) of administration

- ☐ Oral
- ☐ Subcutaneous
- ☐ Intramuscular
- ☐ Topical (Vaginal)
- ☐ Topical (Rectal)
- ☐ Topical (Other)
- ☐ Intra-vitreous
- ☐ Intravenous
- ☐ Transdermal
- ☐ Intra-articular
- ☐ To be determined
- ☐ Other(s)

Type of technology

- ☐ Injectable
- ☐ Non Injectable


Other features of the technology

Development stage

Therapeutic area(s)

Ease of administration


Active Pharmaceutical Ingredient (API)



BEPO®
MEDINCELL

Summary


See more



Extruded Polymer Device (EXPD)
RTI International

Summary

See more



Dissolving microarray patches
Queen's University Belfast

Summary


See more



DelSiTech Silica Matrix Drug Delivery
DelSiTech

Summary

See more



Fatty acid bundles
Immunwork, Inc.

Summary

See more



Drug Combination Nanoparticles (DcNP)
Targeted & Long-acting drug Combination (TLC) Program, University of Washington

Summary

See more

How can you contribute ?

As an **innovator** in the long-acting space, you are developing a long-acting platform which could be applied to **global health**.

You are kindly invited to **provide information** related to your innovation and review a set of **access principles** that would allow members of the community to explore potential **collaborations**.

Tell us about your technology !

- General information
- Technology features
- APIs compatibility
- Technology components
- Scale-up & manufacturing
- Potential applications
- Representative patents
- Supporting information

Show your commitment for access !



Collaborate for development

Consider on a case by case basis, collaborating on developing long-acting products with potential significant public health impact, especially for LMICs, utilising your long-acting technology.



Share information for match-making assessment

Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines might be compatible with the referred to long-acting technology to achieve a public health benefit.



Work with MPP to expand access in LMICs

In the event that a product using the referred to long-acting technology is successfully developed, the technology intellectual property holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in LMICs, including through licensing.

Join this collective effort to centralise essential information & advance a long-acting pipeline with accessible products !




www.lapal.medicinespatentpool.org



lapal@medicinespatentpool.org

LAPaL is coordinated by the Medicines Patent Pool, with support from Unitaïd



**medicines
patent
pool**

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries

Unitaid aims to scale up access to treatment for HIV/AIDS, malaria and tuberculosis for the people in developing countries



Innovation in Global Health

We would like to acknowledge experts' advice from



Long-Acting/Extended Release
Antiretroviral Research Resource Program



for Reproductive Health

